LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA® Phase 2 IIT data in indolent lymphomas to be presented at the 66th American Society of Hematology Annual Meeting in December 2024 Discontinuing ADCT-601 program and prioritizing exatecan-based platform for solid tumors Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland, Nov. 7, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the third quarter ended September 30, 2024, and provided recent operational updates.

Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster presentation of first interim futility analysis of ongoing investigator-initiated Phase 2 clinical trial studying ZYNLONTA as treatment for r/r marginal zone lymphoma LAUSANNE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced independent, investigator-initiated study abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 66th American

LAUSANNE, Switzerland, Nov. 4, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in November: Guggenheim Securities Healthcare Innovation Conference Date: November 11, 2024Presentation Time: 11:00 a.m. ETFormat: Fireside ChatSpeaker: Ameet Mallik, Chief Executive Officer Jefferies London Healthcare Conference Date: November 19, 2024Presentation Time: 11:00 a.m. GMTFormat: Fireside ChatSpeaker: Ameet Mallik, Chief Executive

LAUSANNE, Switzerland, Nov. 1, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 42,000 of the Company's common shares to two new employees on November 1, 2024 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motiv

LAUSANNE, Switzerland, Oct. 31, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, November 7, 2024, at 8:30 a.m. EST to report financial results for the third quarter 2024 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the ev

LAUSANNE, Switzerland, Oct. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 113,700 of the Company's common shares to six new employees on October 1, 2024 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the su

LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 17,900 of the Company's common shares to four new employees on September 3, 2024 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the

LAUSANNE, Switzerland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference Date: September 9, 2024Presentation Time: 7:00 a.m. ETFormat: Virtual Fireside Chat Speaker: Ameet Mallik, Chief Executive Officer 10th Cantor Global Healthcare Conference 2024 Date: September 18, 2024 Presentation Time: 11:30-12:00 p.m. ETFormat: Fireside Chat Speaker: Ameet Mallik, Chief Executive Officer Live webcasts of the presentations will be available via the Events &

ZYNLONTA® net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024 LOTIS-7 trial enrollment on track with efficacy and safety data on eligible patients expected by year-end 2024 and mature data on all patients expected in first half of 2025 Full enrollment in LOTIS-5 trial expected before year-end 2024 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the second quarter ended June 30, 2024, and provided operational updates

LAUSANNE, Switzerland, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 38,600 of the Company's common shares to three new employees on August 1, 2024 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the su

4 - ADC Therapeutics SA (0001771910) (Issuer)

8-K - ADC Therapeutics SA (0001771910) (Filer)

10-Q - ADC Therapeutics SA (0001771910) (Filer)

8-K - ADC Therapeutics SA (0001771910) (Filer)

DEFA14A - ADC Therapeutics SA (0001771910) (Filer)

DEF 14A - ADC Therapeutics SA (0001771910) (Filer)

PRE 14A - ADC Therapeutics SA (0001771910) (Filer)

EFFECT - ADC Therapeutics SA (0001771910) (Filer)

S-3 - ADC Therapeutics SA (0001771910) (Filer)

10-Q - ADC Therapeutics SA (0001771910) (Filer)

8-K - ADC Therapeutics SA (0001771910) (Filer)

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 20 points on Monday. Shares of Intapp, Inc.  (NASDAQ:INTA) fell sharply in today's pre-market trading after Oppenheimer downgraded the stock from Outperform to Perform. Intapp shares tumbled 4.5% to $ 34.67 in the pre-market trading session. Here are some big stocks recording losses in today's pre-market trading session. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) shares dipped 16.2% to $8.79 in pre-market trading. Arcutis Biotherapeutics, last week, reported inducement grants under Nasdaq Listing Rule 5635(c)(4). ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) shares declined 6.4% to $

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on ADC Therapeutics (NYSE:ADCT) with a Overweight rating.

HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $9 to $8.

U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Monday. Shares of BioNTech SE (NASDAQ:BNTX) fell sharply in today's pre-market trading following weaker-than-expected first-quarter earnings. BioNTech posted quarterly GAAP loss of €1.31 per share, missing estimates of €0.97 per share. The company's sales came in at €187.600 million missing estimates of €427.500 million. BioNTech shares fell 4.4% to $88.65 in pre-market trading in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Medical Properties Trust, Inc (NYSE:MPW) shares declined 14.4% to $4.17 in pre-market trading after tenant

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.56) by 32.14 percent. The company reported quarterly sales of $18.053 million which missed the analyst consensus estimate of $18.102 million by 0.27 percent. This is a 4.94 percent decrease over sales of $18.992 million the same period last year.

ADC Therapeutics SA (NYSE:ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL).

U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.1% on Tuesday. Shares of Medifast, Inc. (NYSE:MED) fell sharply in today's pre-market trading after the company reported mixed first-quarter financial results. Medifast posted adjusted earnings of 66 cents per share, missing market estimates of 78 cents per share. The company's quarterly sales came in at $174.739 million versus expectations of $168.900 million, according to data from Benzinga Pro. Medifast shares tumbled 15.6% to $29.95 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Coursera, Inc. (NYSE:COUR) shares dipped 12.7

HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $9 price target.

Stephens initiated coverage of ADC Therapeutics with a rating of Overweight and set a new price target of $6.00

Cantor Fitzgerald initiated coverage of ADC Therapeutics with a rating of Overweight

Guggenheim initiated coverage of ADC Therapeutics with a rating of Buy and set a new price target of $11.00

JP Morgan upgraded ADC Therapeutics from Underweight to Neutral

BofA Securities downgraded ADC Therapeutics from Neutral to Underperform and set a new price target of $2.00 from $7.00 previously

CapitalOne initiated coverage of ADC Therapeutics with a rating of Overweight and set a new price target of $12.00

BofA Securities downgraded ADC Therapeutics from Buy to Neutral and set a new price target of $7.00 from $14.00 previously

JP Morgan initiated coverage of ADC Therapeutics with a rating of Overweight and set a new price target of $5.00

Morgan Stanley downgraded ADC Therapeutics from Overweight to Equal-Weight and set a new price target of $11.00 from $17.00 previously

HC Wainwright & Co. reiterated coverage of ADC Therapeutics with a rating of Buy and set a new price target of $54.00 from $55.00 previously

£90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova PartnersFunds will be used to build out Myricx Bio's proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigensCompany to establish laboratory operations in London's biotech hub, and expand its management and R&D teamsMichael Bauer from Novo Holdings and Lucille Conroy from Abi

LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. "We are pleased to be joining the Russell 2000® Index," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This is a significant benchmark validating the focused execution of our corporate and capital allocation strategy and our progress toward multiple upcoming expected milestones throughout our hematology and solid tumor portfolios." Th

LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), today announces the appointment of Dr Chris Martin as independent Chairman to its Board of Directors. Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space. Dr Martin was instrumental in co-founding ADC Therapeutics (NYSE:ADCT) in Jan 2012 and served as its CEO since inception until May 2022. Under his leadership, ADC Therapeutics grew from a private biotech start-up to a New York

LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibody-drug conjugates (ADCs), today announces the appointment of Francesca Zammarchi, Ph.D., as Chief Scientific Officer (CSO). Dr. Zammarchi joins Myricx as it accelerates the development of its pipeline of ADCs based on its first-in-class N-myristoyltransferase inhibitor (NMTi) payload platform. She brings over two decades of cancer biology research experience, including developing ADCs, gained working in the biopharma industry and in academia. At Myricx, as a senior member of the Leadership T

Strengthens the Board with the election of Robert W. Azelby as director Board will be comprised of nine directors; gratitude expressed for contributions of outgoing directors LAUSANNE, Switzerland, June 15, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced the election of Robert W. Azelby to its Board of Directors. Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial experience to ADC Therapeutics' Board. "We're delighted to welcome Bob to our Board. He brings with him a wealth of experience and a strong track record in building successful biotech companies. This expertise will be invaluable at this time as we execu

ADC Therapeutics SA (NYSE:ADCT) today announced the appointment of industry veteran Mohamed Zaki, MD, PhD, as Chief Medical Officer (CMO), effective January 3, 2023. He will serve on the Company's executive leadership team. Dr. Zaki succeeds Joseph Camardo, MD, who is stepping down from full-time work to pursue other avenues to engage with the pharmaceutical industry and patient community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230103005766/en/Mohamed Zaki, MD, PhD, Chief Medical Officer, ADC Therapeutics (Photo: Business Wire) "We are excited to welcome Dr. Zaki to ADC Therapeutics and look forward to his leadership of t

ADC Therapeutics SA (NYSE:ADCT) today announced the appointment of Jose "Pepe" Carmona as Chief Financial Officer (CFO), effective December 19, 2022. He will serve on the Company's executive leadership team and succeeds Jenn Creel, who is leaving to pursue other opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221219005210/en/Jose Carmona, Chief Financial Officer, ADC Therapeutics (Photo: Business Wire) "We warmly welcome Pepe to ADC Therapeutics. As we enter the next phase of growth, I am confident that his extensive financial background, deep capital markets experience and proven leadership in the pharmaceutical in

ADC Therapeutics SA (NYSE:ADCT) today announced the appointment of Kristen Harrington-Smith as Chief Commercial Officer, effective November 17, 2022. The Company also announced the appointment of Peter Graham as Chief Legal Officer, effective November 1, 2022. Both Ms. Harrington-Smith and Mr. Graham will serve on the Company's leadership team. Kristen Harrington-Smith appointed as Chief Commercial Officer "We are delighted to welcome Kristen to ADC Therapeutics. She has an extraordinary commercial background in the DLBCL landscape having led the commercial teams for serious hematological diseases, including major launches of innovative cell therapy products. We have complete conviction t

Ameet Mallik, Chief Executive Officer of ADC Therapeutics, also joins the Board ADC Therapeutics SA (NYSE:ADCT) today announced the appointment of veteran oncology drug developer Jean-Pierre Bizzari, MD, to its Board of Directors. Additionally, Ameet Mallik, who was appointed as the Company's Chief Executive Officer in May 2022, will join the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220701005047/en/Jean-Pierre Bizzari, MD (Photo: Business Wire) "Jean-Pierre is an exceptional addition to our Board," said Ron Squarer, Chairman of ADC Therapeutics' Board of Directors. "His integral role in the development and approval

Co-Founder Chris Martin transitions CEO role to industry veteran Ameet Mallik Dr. Martin to serve on Board of Directors and as Chair of the Science and Technology Committee ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced that Chris Martin, DPhil, has stepped down as Chief Executive Officer. Dr. Martin will serve as a non-executive member of the Company's Board of Directors and Chair of the Science and Technology Committee. He will also serve as an advisor to the Company for the ne